BEI
MCRB icon

Benjamin Edwards Inc’s Seres Therapeutics MCRB Stock Holding History

Benjamin Edwards Inc’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-34
Closed -$16K – 545
2021
Q2 		$16K Sell
34
-11
-24% -$4.64K 0.01% 347
2021
Q1 		$19K Buy
45
+1
+2% +$460 0.01% 302
2020
Q4 		$22K Sell
44
-15
-25% -$8.78K 0.02% 291
2020
Q3 		$33K Sell
59
-8
-12% -$2.66K 0.03% 251
2020
Q2 		$6K Hold
67
– – 0.01% 327
2020
Q1 		$5K Buy
67
+3
+5% +$201 0.01% 322
2019
Q4 		$4K Buy
64
+3
+5% +$222 0.01% 262
2019
Q3 		$5K Sell
61
-4
-6% -$264 0.01% 258
2019
Q2 		$4K Buy
65
+30
+86% +$2.85K 0.01% 274
2019
Q1 		$5K Buy
+35
New +$4.27K 0.02% 245

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Benjamin Edwards Inc's MCRB Position: Q3 2021 in Review

Benjamin Edwards Inc sold out of Seres Therapeutics (MCRB) in Q3 2021, closing a stake of 34 shares — an estimated $16K sold.

Benjamin Edwards Inc first reported a position in MCRB in Q1 2019 and held it in 10 quarters. The position peaked at $33K in Q3 2020. 133 funds tracked by Wall St. Rank hold MCRB as of Q3 2021.

  • Benjamin Edwards Inc reported no remaining Seres Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Benjamin Edwards Inc sold 34 Seres Therapeutics shares in Q3 2021, an estimated $16K.
  • Benjamin Edwards Inc first reported a position in Seres Therapeutics in Q1 2019 and held it in 10 quarters.
  • Benjamin Edwards Inc's Seres Therapeutics position peaked at $33K in Q3 2020.
  • 133 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2021.

Based on Benjamin Edwards Inc's 13F filing for Q3 2021, filed 2 Nov 2021.